Gene Therapy for X-CGD

NCT ID: NCT01906541

Last Updated: 2013-08-02

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 5 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-07-31
• Study Completion Date: 2019-12-31

Brief Summary

X-linked chronic granulomatous disease (X-CGD) is a rare inherited immune defect, which is caused by the inability of phagocytic cells to produce reactive oxygen species due to a defect in the gp91phox subunit of the NADPH oxidase complex. X-CGD patients suffer from recurrent and life-threatening infections and severe hyperinflammatory complications.

The only curative treatment for X-CGD is allogenic hematopoietic stem cell transplantation, but this procedure implies severe risks and many patients lack an appropriate donor. Therefore alternative curative approaches are urgently needed. In this study, patients will be treated with gene-corrected autologous CD34+ cells, using a SIN gammaretroviral vector for ex-vivo gene-therapy.

Conditions

X-linked Chronic Granulomatous Disease

Keywords

X-CGD; chronic granulomatous disease; gene-therapy

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

ex-vivo gene-therapy

transplantation of genetically modified autologous CD34+ cells

Group Type: EXPERIMENTAL

ex-vivo gene-therapy

Intervention Type: GENETIC

transplantation autologous CD34+ cells, transduced with a SIN gammaretroviral vector

Interventions

ex-vivo gene-therapy

transplantation autologous CD34+ cells, transduced with a SIN gammaretroviral vector

Intervention Type: GENETIC

Eligibility Criteria

Inclusion Criteria

• Verified diagnosis of the X-linked form of chronic granulomatous disease, with loss of gp91phox expression (Western Blot). Evidence of less than 5% of normal oxidase production in circulating neutrophil granulocytes as measured by dihydrorhodamine- (DHR-) and nitro blue tetrazolium- (NBT-) assay
• History of severe chronic infections with life-threatening course or severe steroid- sensitive or steroid insensitive granulomatous disease, with necessity of inpatient treatment, without sustained improvement even under maximum conservative treatment measures
• No Human Leukocyte Antigen (HLA) identical (10/10 match) sibling- or unrelated donor, or contraindications for allogenic stem cell transplantation in presence of a suitable donor. The lack of an HLA-identical (10/10 match) sibling- or unrelated donor has to be confirmed by an unsuccessful search in national and international donor registers for at leat 3 months
• Normal organ-function: glomerular filtration rate (GFR) ≥ 60ml/min., Bilirubin ≤ 1.5-fold upper reference-level, normal parameters for liver enzymes and clotting (TPZ 75-100%, partial thromboplastin time (PTT) 30-38sec, Fibrinogen 200-400mg/dl), Leukocytes > 3 x 10^9/l, Granulocytes > 1.5 x 10^9/l, Thrombocytes >100 x 10^9/l
• Contraception from start of G-CSF application until 1 year after retransfusion of the gene-corrected cells
• No interferon-gamma injection within two weeks prior to hematopoietic stem cell mobilization
• Karnofsky-Index > 70%
• Signed informed consent

Exclusion Criteria

• Patients with non-controlled acute infections
• Severe cardiac or pulmonary malfunctions: ejection fraction < 60%, valvular heart disease > II°, arrhythmia requiring therapy, forced expiratory volume at one second/vital capacity (FEV1/VC) < 75% , diffusion capacity of lung for carbon monoxide (DLCO) <60%
• Bilirubin > 1.5-fold upper reference-level
• HIV-, Hepatitis B- or C - infection
• Contraindications for G-CSF administration, as autoimmune vasculitis.
• Contraindications for stem cell apheresis, as low hemoglobin < 8g/dl, cardiovascular instability or severe coagulopathy
• Pregnancy or breast-feeding
• Drug- or alcohol-abuse
• Lack of search for an unrelated donor
• Patients with a HLA 9/10 mismatched unrelated donor (MMUD) will be excluded, if a thorough risk-benefit analysis favors allogenic hematopoietic stem cell transplantation (HSCT)

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Hubert Serve, Prof., MD

OTHER

Sponsor Role: lead

Responsible Party

Hubert Serve, Prof., MD

Head of Medical Department II

Responsibility Role: SPONSOR_INVESTIGATOR

Locations

University Hospital Frankfurt

Frankfurt am Main, , Germany

Site Status: RECRUITING

Countries

Germany

Central Contacts

Hubert Serve, Prof., MD

Role: CONTACT

Phone: 0049/69/6301

Email: serve@em.uni-frankfurt.de

Joachim Schwäble, MD

Role: CONTACT

Phone: 0049/69/67824900

Email: schwaeble@em.uni-frankfurt.de

Facility Contacts

Joachim Schwäble, MD

Role: primary

Other Identifiers

X-CGD

Identifier Type: -

Identifier Source: org_study_id